Nature Communications (Jan 2021)
A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication
- Shin-ichiro Hattori,
- Nobuyo Higashi-Kuwata,
- Hironori Hayashi,
- Srinivasa Rao Allu,
- Jakka Raghavaiah,
- Haydar Bulut,
- Debananda Das,
- Brandon J. Anson,
- Emma K. Lendy,
- Yuki Takamatsu,
- Nobutoki Takamune,
- Naoki Kishimoto,
- Kazutaka Murayama,
- Kazuya Hasegawa,
- Mi Li,
- David A. Davis,
- Eiichi N. Kodama,
- Robert Yarchoan,
- Alexander Wlodawer,
- Shogo Misumi,
- Andrew D. Mesecar,
- Arun K. Ghosh,
- Hiroaki Mitsuya
Affiliations
- Shin-ichiro Hattori
- Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute
- Nobuyo Higashi-Kuwata
- Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute
- Hironori Hayashi
- Department of Intelligent Network for Infection Control, Tohoku University Hospital
- Srinivasa Rao Allu
- Department of Chemistry and Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University
- Jakka Raghavaiah
- Department of Chemistry and Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University
- Haydar Bulut
- Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health
- Debananda Das
- Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health
- Brandon J. Anson
- Department of Biochemistry and Department of Biological Sciences, Purdue University
- Emma K. Lendy
- Department of Biochemistry and Department of Biological Sciences, Purdue University
- Yuki Takamatsu
- Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute
- Nobutoki Takamune
- Kumamoto Innovative Development Organization, Kumamoto University
- Naoki Kishimoto
- Department of Environmental and Molecular Health Sciences, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University
- Kazutaka Murayama
- Graduate School of Biomedical Engineering, Tohoku University
- Kazuya Hasegawa
- Protein Crystal Analysis Division, Japan Synchrotron Radiation Research Institute
- Mi Li
- Protein Structure Section, Center for Structural Biology, National Cancer Institute
- David A. Davis
- Viral Oncology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health
- Eiichi N. Kodama
- Department of infectious Diseases, International Research Institute of Disaster Science, Tohoku University
- Robert Yarchoan
- Viral Oncology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health
- Alexander Wlodawer
- Protein Structure Section, Center for Structural Biology, National Cancer Institute
- Shogo Misumi
- Department of Environmental and Molecular Health Sciences, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University
- Andrew D. Mesecar
- Department of Biochemistry and Department of Biological Sciences, Purdue University
- Arun K. Ghosh
- Department of Chemistry and Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University
- Hiroaki Mitsuya
- Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute
- DOI
- https://doi.org/10.1038/s41467-021-20900-6
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 12
Abstract
Here, using in vitro assays and structural analysis, the authors characterize the anti-SARS-CoV-2 properties of two small molcules, showing these to bind and target the virus main protease (Mpro), and to exhibit a synergistic antiviral effect when combined with remdesivir in vitro.
